Two Steps Forward and One Step Back for Precision in Prostate Cancer Treatment

doi:10.1200/JCO.20.01755

. 2020 Nov 10;38(32):3740-3742.

doi: 10.1200/JCO.20.01755. Epub 2020 Sep 8.

Two Steps Forward and One Step Back for Precision in Prostate Cancer Treatment

Michael T Schweizer^{1

2}, Heather H Cheng^{1

2}, Peter S Nelson^{1

2

3}, R Bruce Montgomery^{1

2

4}

Affiliations

¹ Division of Oncology, Department of Medicine, University of Washington, Seattle, WA.
² Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
³ Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA.
⁴ VA Puget Sound Health Care System, Seattle, WA.

PMID: 32897829
PMCID: PMC8265388
DOI: 10.1200/JCO.20.01755

Two Steps Forward and One Step Back for Precision in Prostate Cancer Treatment

Michael T Schweizer et al. J Clin Oncol. 2020.

. 2020 Nov 10;38(32):3740-3742.

doi: 10.1200/JCO.20.01755. Epub 2020 Sep 8.

Authors

Michael T Schweizer^{1

2}, Heather H Cheng^{1

2}, Peter S Nelson^{1

2

3}, R Bruce Montgomery^{1

2

4}

Affiliations

¹ Division of Oncology, Department of Medicine, University of Washington, Seattle, WA.
² Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
³ Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA.
⁴ VA Puget Sound Health Care System, Seattle, WA.

PMID: 32897829
PMCID: PMC8265388
DOI: 10.1200/JCO.20.01755

No abstract available

PubMed Disclaimer

Cited by

DNA-Damaging Therapies in Patients With Prostate Cancer and Pathogenic Alterations in Homologous Recombination Repair Genes.
Graham LS, Henderson NC, Kellezi O, Hwang C, Barata PC, Bilen MA, Kilari D, Pierro M, Thapa B, Tripathi A, Mo G, Labriola M, Park JJ, Rothstein S, Garje R, Koshkin VS, Patel VG, Dorff T, Armstrong AJ, McKay RR, Alva A, Schweizer MT. Graham LS, et al. JCO Precis Oncol. 2024 Aug;8:e2400014. doi: 10.1200/PO.24.00014. JCO Precis Oncol. 2024. PMID: 39178368
Genomic Correlates of Prostate-Specific Membrane Antigen Expression and Response to ¹⁷⁷Lu-PSMA-617: A Retrospective Multicenter Cohort Study.
Raychaudhuri R, Mo G, Tuchayi AM, Graham L, Gulati R, Pritchard CC, Haffner MC, Yezefski T, Hawley JE, Cheng HH, Yu EY, Grivas P, Montgomery RB, Nelson PS, Chen DL, Hope T, Iravani A, Schweizer MT. Raychaudhuri R, et al. JCO Precis Oncol. 2024 Apr;8:e2300634. doi: 10.1200/PO.23.00634. JCO Precis Oncol. 2024. PMID: 38662984
Management of Advanced Prostate Cancer in the Precision Oncology Era.
Gillette CM, Yette GA, Cramer SD, Graham LS. Gillette CM, et al. Cancers (Basel). 2023 Apr 29;15(9):2552. doi: 10.3390/cancers15092552. Cancers (Basel). 2023. PMID: 37174018 Free PMC article. Review.
Prostate cancer risk, screening and management in patients with germline BRCA1/2 mutations.
Rajwa P, Quhal F, Pradere B, Gandaglia G, Ploussard G, Leapman MS, Gore JL, Paradysz A, Tilki D, Merseburger AS, Morgan TM, Briganti A, Palapattu GS, Shariat SF. Rajwa P, et al. Nat Rev Urol. 2023 Apr;20(4):205-216. doi: 10.1038/s41585-022-00680-4. Epub 2023 Jan 4. Nat Rev Urol. 2023. PMID: 36600087 Review.
Homologous Recombination Repair Gene Variants and Outcomes Among Patients With Prostate Cancer Treated With Poly (ADP-ribose) Polymerase Inhibitors.
Price MJ, Vashistha V, Winski D, Kelley MJ, Bitting RL, Montgomery B. Price MJ, et al. JCO Precis Oncol. 2022 Apr;6(1):e2100461. doi: 10.1200/PO.21.00461. JCO Precis Oncol. 2022. PMID: 35476551 Free PMC article.

See all "Cited by" articles

References

1. US Food and Drug Administration : Rubraca package insert. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209115s003lbl.pdf
1. US Food and Drug Administration : Lynparza package insert. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208558s001lbl.pdf
1. Abida W, Bryce AH, Vogelzang NJ, et al. : Preliminary results from TRITON2: A phase 2 study of rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination repair (HRR) gene alterations. Ann Oncol 29, 2018. (suppl 8; abstr 793PD)
1. de Bono J, Mateo J, Fizazi K, et al. : Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med 382:2091-2102, 2020 - PubMed
1. Abida W, Campbell D, Patnaik A, et al. : Non-BRCA DNA damage repair gene alterations and response to the PARP inhibitor rucaparib in metastatic castration-resistant prostate cancer: Analysis from the phase II TRITON2 study. Clin Cancer Res 26:2487-2496, 2020 - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

P50 CA097186/CA/NCI NIH HHS/United States

LinkOut - more resources

Full Text Sources

[1] US Food and Drug Administration : Rubraca package insert. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209115s003lbl.pdf

[2] US Food and Drug Administration : Rubraca package insert. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209115s003lbl.pdf

[3] US Food and Drug Administration : Lynparza package insert. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208558s001lbl.pdf

[4] US Food and Drug Administration : Lynparza package insert. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208558s001lbl.pdf

[5] Abida W, Bryce AH, Vogelzang NJ, et al. : Preliminary results from TRITON2: A phase 2 study of rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination repair (HRR) gene alterations. Ann Oncol 29, 2018. (suppl 8; abstr 793PD)

[6] Abida W, Bryce AH, Vogelzang NJ, et al. : Preliminary results from TRITON2: A phase 2 study of rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination repair (HRR) gene alterations. Ann Oncol 29, 2018. (suppl 8; abstr 793PD)

[7] de Bono J, Mateo J, Fizazi K, et al. : Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med 382:2091-2102, 2020 - PubMed

[8] de Bono J, Mateo J, Fizazi K, et al. : Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med 382:2091-2102, 2020 - PubMed

[9] Abida W, Campbell D, Patnaik A, et al. : Non-BRCA DNA damage repair gene alterations and response to the PARP inhibitor rucaparib in metastatic castration-resistant prostate cancer: Analysis from the phase II TRITON2 study. Clin Cancer Res 26:2487-2496, 2020 - PMC - PubMed

[10] Abida W, Campbell D, Patnaik A, et al. : Non-BRCA DNA damage repair gene alterations and response to the PARP inhibitor rucaparib in metastatic castration-resistant prostate cancer: Analysis from the phase II TRITON2 study. Clin Cancer Res 26:2487-2496, 2020 - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Two Steps Forward and One Step Back for Precision in Prostate Cancer Treatment

Affiliations

Two Steps Forward and One Step Back for Precision in Prostate Cancer Treatment

Authors

Affiliations

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full Text Sources